very interesting new idea brought to my attention by RHPS today.

http://www.phosphagenics.com/ is the company website and

www.cohenresearch.com has an interesting report on them

with new phosphorylation techniques (inserting a phosphate group into the chemical structure to make it much more readily absorbed into the body), they aim to deliver more effectively previously hard to transmit drugs to the body - Vitamin E (already successfully launched in US), morphine (much smaller amounts needed, so fewer side effects), and others

talks with FDA started on basis of an enhanced delivery rather than enhanced drug action - much simpler process

recently gained Aus government grant of Aus$1.7 to fund Phase I and Pre-Phase II human trials of transdermal morphine delivery

a Material Evaluation Agreement signed with major US pharma to apply PSG's technology to its patented systems

forward PE of 0.54 (yes I did get the decimal point in the right place!)

shares up from about 7p to 12p over last 3 months

listed on Ausraillian Stock Market and London AIM

must be interesting to watch at least. DYOR then do it again to make sure I'm not dreaming.

check it out and ket me know what you think

cheers
SD

Just wait till their vitamin E in soluble form gets approval to attack (sic) the heart market - bigger than morphine and bigger even than insulin market - 3 immense areas of growth aprt from the nutriceuticals opportunities. remember Astra Zedneca, Welcome, etc, etc I can still remember when they were this size - just.

sd

hi stockdog, followed you over here a few weeks ago and now thinking strongly towards getting in...though the years chart doesn't look to encouraging

GN

Glob Nom, the chart stinks, I know. But at this stage of a company in a very thin market for the shares, the chart is probably not so relevant.

Having studied chemistry at university, I have an affinity with the basic process they are doing here - phophorylation. It's "making a better light bulb" whose applications are literally endless. Just take soluble Vitamin E for cardiovascular and transdermal delivery of post-operative morphine and diabetic insulin, not to mention the more fashionable nutraceuticals. These two or three products are selling in to multi-billion dollar markets with no visible competition to the improvement they will offer once fully tested and approved. Approval for a new method of delivery is much less difficult than approval for a new drug per se.

So far they have proved themselves at each stage of technological development and regulatory approval, but I am sure we may still be some years away from break out. However, I have no problem imagining that this share could be 1.15 in 5 years time. The down side seems to have been mostly shaken out since I bought in at about 13.70 over the first 6 months of last year, barring any specific bad news, like failure to gain approval at any future stage. Although I'm down 23%, it's kind of irrellevant compared to the upside that will eventually out when the market is prepared to look at these seriously.

I'm a little light in my poprtfolio weighting on this one and it's one of my targets to top up as soon as any profit trimming (or stop lossing!) on other stocks frees up some more cash.

You (I) could have got in at 10.50p at the start of the year, as oppopsed to 12.50p offer now. But it will make no real difference to the proposition and the chances are equally likely we'll never see 10.50p again anyway.

So take a dabble, or paddle, or whatever it is you do to get your toes wet. This will give you an interest to get to learn all about this share and keep you awake for the time to put in serious money when it starts to make its first major move upwards.

WDIK, DYOR

sd

cheers SD, I think I've got my shoes and socks off but the water looks a little chilly......a little encouragement (or a push) and my toes will get dipped then I may well go for a swim.

GN

I'll hold the towel for you, but you've gotta make the ultimate decision. Good luck.

sd

Annual accounts published yesterday - the most boring uninformative stuff I've read in years, although full marks for thorough transparency. Unfortunately it tells you mor about Oz accounting standards than it does about the company. One small fact I gleaned is that Nutraceuticals division fulfilled last year's AGMS's prediction of breaking even in 2005 with a small profit of about Aus$111,000 - although who knows how the allocate central costs quite.

Frustrated by no proper Chairman or CEO's report on the activities of the company in the accounts I looked on their website and found 3 very nice reports from the AGM last May - see links below:-

http://www.phosphagenics.com/main/investors_presentations.htm

and a brokers update from Nov 2005 which makes good reading, valuing the SP at Aus$0.71 or about 28p compared to today's 10p:-

http://www.phosphagenics.com/main/Analyst_Coverage.htm

This is very much on my list to buy more whilst still at this price, when I can bear to free up some cash from my other holdings. Let's hope this year's AGM has as much to say about the company's activities and achievements as last years.

sd

I saw by chance the following report of a deal with Nestle Nutrition which may account for today's meteoric 0.25p rise. Why doesn't MaM pick this up in their RNS reports? Anyway, even though the SP has turned into a snail, one day all this positive progress will bear fruit IMHO.

sd

28 April 2006
PHOSPHAGENICS & NESTLNUTRITION SIGN AGREEMENT FOR DEVELOPMENT OF PHOSPHA E
FOR FOODS AND BEVERAGES
Melbourne, Australia and Vevey, Switzerland, 28 April 2006 Phosphagenics
Limited ("Phosphagenics"), the Australian Stock Exchange (ASX : POH) and the
London Stock Exchange's Alternative Investment Market (AIM : PSG) listed
pharmaceutical and nutraceutical company, and Nestlé Nutrition, a unit of
Nestlé S.A. the world's biggest food and beverage company, today announce that
they have entered into a research agreement to develop Phosphagenics' Phospha E
® for use in Nestlé Nutrition's products. Products containing this superior
form of vitamin E have the potential to play a role in the prevention and
treatment of metabolic syndrome.
Under the terms of the agreement, Nestlé Nutrition will contribute some of the
funding towards a full dose-response preclinical study of Phospha E®, before
full scale evaluation of the product in humans. Phospha E® has been shown in
animal trials to lower blood cholesterol and triglyceride levels and to prevent
or reduce arterial plaque formation, as well as inhibiting the main
inflammatory pathways involved in metabolic syndrome.
In return, Nestlé Nutrition has obtained an option to license Phospha E® for
its use in nutritional products that target the prevention and treatment of
metabolic syndrome. Upon completion of the preclinical trials, Nestlé Nutrition
may exercise its option, upon payment of an option fee. The agreement requires
that Nestlé Nutrition launch a product within 12 months of regulatory approval
of the product and claims, and that Phosphagenics will be responsible for the
manufacture of and sale to Nestle Nutrition of Phospha E®.
Harry Rosen, Managing Director of Phosphagenics, said "Phosphagenics is
delighted to have signed this agreement with Nestlé Nutrition, which builds on
our collaborative work so far. As one of the world's largest nutrition
companies, Nestlé Nutrition is the ideal partner to exploit the potential of
Phospha E® in nutritional products".
END
About metabolic syndrome
Metabolic syndrome is a multifactorial risk factor for cardiovascular disease
and diabetes. The root causes of metabolic syndrome are overweight/obesity,
physical inactivity, and genetic factors. It is estimated that about 27% of
adults in the US have metabolic syndrome and that one in three overweight or
obese people in the US have this condition. The condition is being diagnosed
with increasing frequency.
About Phosphagenics
Phosphagenics is a pharmaceutical and nutraceutical company with a diversified
portfolio of technologies encompassing drug delivery, drug enhancement, and
active ingredients for dietary supplements, functional foods and personal care
products. It is based in Melbourne, Australia. Its shares are listed on the
Australian Stock Exchange (POH) and the London Stock Exchange's Alternative
Investment Market (PSG). Further information regarding Phosphagenics can be
found at www.phosphagenics.com.
About Nestlé Nutrition
Nestlé Nutrition is an autonomous business operation within the Nestlé group
that manages and develops the group's core nutrition business. Through
science-based nutrition products and services, Nestlé Nutrition will help
enhance the quality of people's lives by supporting health and providing care
for specific consumer groups with special nutrition needs at every stage of
life. Its product portfolio - covering infant nutrition, healthcare nutrition,
and performance nutrition - includes such trusted and well-recognised brands
as: NAN, LACTOGEN, NESLAC, NUTREN, PEPTAMEN and POWERBAR.
For further information please contact:
Australia:
Phosphagenics Limited : Harry Rosen, Managing Director
Telephone: +61 3 9605 5900
UK:
Northbank Communications: Rowan Minnion
Telephone: +44 7886 8150
r.minnion@northbankcommunications.com
END

That's what I've got!! metabolic syndrome-where can I buy some??? lol

hmmm interesting share stockdog... wonder if these will drift some more before the perfect entry point (reading the research note, they do seem to have alot of potential)

2006-05-08 07:01:34
Phosphagenics Limited - Research Update
Phosphagenics initiates Phase 2a clinical trial of its transdermal morphine
cream

Melbourne, VIC, Australia, 8 May 2006

Phosphagenics Limited ("Phosphagenics"), the Australian Stock Exchange (ASX:
POH) and the London Stock Exchange's Alternative Investment Market (AIM:PSG)
listed pharmaceutical and nutraceutical company, today announces commencement
of a Phase 2a clinical trial of its transdermal morphine cream, TPM-01/
Morphine. The Phase 2a trial, investigating the efficacy, absorption, and
metabolism of morphine administered using Phosphagenics' novel transdermal
carrier TPM-01, will be conducted at the Royal Adelaide Hospital, South
Australia. Preliminary results are expected during the third quarter of 2006.

In the trials, doses of morphine will be examined in 48 healthy male volunteers
aged between 18 and 49 years. Volunteers will be randomly assigned into a dose
group and either receive active treatment or placebo treatment in a double
blinded manner. The efficacy of Phosphagenics transdermal morphine in producing
the well recognised effects of morphine in humans, such as changes in pupil
size and decreased response to painful stimuli, will be measured.

Dr Esra Ogru, Executive Director of Research and Development at Phosphagenics,
said: "The initiation of phase 2a clinical trials of morphine with our
proprietary transdermal delivery technology is a significant milestone in the
development or our pain management product. It will also provide further
clinical proof of the efficacy of Phosphagenics' transdermal delivery
technology."

About Phosphagenics' Transdermal Morphine

Phosphagenics' transdermal morphine (TPM-01/Morphine) is a non-invasive,
patient-friendly gel or cream that delivers morphine through the skin into the
bloodstream. Previous clinical trials of TPM-01/Morphine have achieved 48 hours
of therapeutic morphine blood levels from a single dose, which compares
favourably to the longest acting morphine products available which provide only
up to 24 hours of therapeutic blood levels per dose.

Phosphagenics expects that a transdermal product capable of providing
therapeutic blood levels of morphine for 48 hours or longer would fill an unmet
clinical need for chronic pain patients (by minimising the occurrence of
"breakthrough pain") and provide cost-effective treatment solutions for hospice
patients, especially those unable to swallow oral preparations of morphine.
There is currently no commercially available transdermal morphine product.

ENDS

Notes to Editors

About Phosphagenics' Transdermal Carrier Technology

Phosphagenics patented transdermal technology is a carrier that utilises
existing natural transport mechanisms to "carry" drugs across the skin without
disrupting the surface of the skin. In contrast, alternative transdermal
technologies either: rely on passive diffusion across skin membranes improving
drug penetration with solvents, enhancers or lasers that modify the properties
of the outermost layers of the skin; or, use electrical or thermal technologies
to "push" drugs through the skin.

Both formulations of the carrier (TPM-01 and TPM-02) have anti-inflammatory and
anti-erythema properties which minimise skin irritation, can provide sustained
transdermal delivery of drugs and can deliver a range of drugs through the
skin. TPM-01 delivers small molecule drugs (e.g. morphine, fentanyl, oxycodone,
atropine, estradiol, testosterone) and TPM-02 delivers both small and large
molecule drugs (e.g. insulin, PTH, proteins).

About Phosphagenics Limited

Phosphagenics is a pharmaceutical and nutraceutical company with a diversified
portfolio of technologies encompassing drug delivery, drug enhancement, and
active ingredients for the nutraceutical industry (dietary supplements,
functional foods and personal care products).

Phosphagenics is based in Melbourne, Australia. Its shares are listed on the
Australian Stock Exchange (POH) and the London Stock Exchange's Alternative
Investment Market (PSG). An American Depository Receipts-Level 1 facility has
been established in the US with the Bank of New York (PPGNY) for the trading of
the Company's shares in the US `Over the Counter' market. Further information
regarding Phosphagenics can be found at www.phosphagenics.com.

For further information please contact:

Phosphagenics Limited:

Dr Esra Ogru, Executive Director Research & Development

Ph: +61 3 9605 5900 or 0402 080 846

Northbank Communications

Rowan Minnion

Ph: +44 (0)20 7886 8150

r.minnion@northbankcommunications.com




END

.

Mention in shares mag today. Not read it, got it from todays news paper round up.

Plays of the Week: Buy Manganese Bronze at 222.5p - Financial Objects at 46p

Updates: Buy Ascribe and Titan Europe

Something in the Pipeline: Protherics - Skyepharma - Alizyme - Plethora Solutions - Ark Therapeutics - Phosphagenics - Ardana

.

hang on, forest, I'll just get my micro-dot reader!

sd

Thats what my mrs says!! LOL not.

over 7 million traded in oz last night, up 6.5%. Take a look at chart from start of 2004 just b4 the large spike, very similar to the one we have now. (The four steps)

Reason for dot, phone rang and had to go out. easy to find psg when i got back.

Any further developments since Shares' mention to cause the welcome lift in price last week, on reasonable volume too?

Next stop Jan's 15.5p highs?

sd

23 August 2006

Phosphagenics Limited

On 22 August 2006, the Australian Stock Exchange ("ASX") published a response
by the Company to an ASX query regarding a change in the Company's share price.
Both the published query and response are set out below:

Query:

21 August 2006

Mourice Garbutt

Company Secretary

Phosphagenics Limited

By Email only

Dear Mourice

Phosphagenics Limited (the "Company")

RE: PRICE QUERY

We have noted a change in the price of the Company's securities from a low of
$0.29 on 7 August 2006 to $0.365 at the time of writing. We have also noted an
increase in the volume of trading in the securities over this period.

In light of the price change and increase in volume, please respond to each of
the following questions.

1. Is the Companyaware of any information concerning it that has not been
announced which, if known, could be an explanation for recent trading in
the securities of the Company?

2. If the answer to question 1 is yes, can an announcement be made
immediately? If not, why not and when is it expected that an announcement
will be made?

Please note, if the answer to question 1 is yes and an announcement cannot be
made immediately, you need to contact us to discuss this and you need to
consider a trading halt (see below).

3. Is there any reason to think that there may be a change in the operating
loss before abnormal items and income tax so that the figure for the half year
ended 30 June 2006 would vary materially from the previous corresponding
period. If so, please provide details as to the extent of the likely variation.

4. Is there any reason to think that the Company may record any material
abnormal or extraordinary items for the half year ended 30 June 2006? If so,
please provide details.

5. Is there any other explanation that the Company may have for the price
change and increase in volume in the securities of the Company?

6. Please confirm that the Company is in compliance with the listing rules and,
in particular, listing rule 3.1.

Your response should be sent to me by return e-mail or by facsimile on
facsimile number (03) 9614 0303. It should not be sent to the Company
Announcements Office.

Unless the information is required immediately under listing rule 3.1, a
response is requested as soon as possible and, in any event, not later than
half an hour before the start of trading (ie before 9.30 a.m. ) on Tuesday, 22
August 2006).

Under listing rule 18.7A, a copy of this query and your response will be
released to the market, so your response should be in a suitable form and
separately address each of the questions asked. If you have any queries or
concerns, please contact me immediately.

Listing rule 3.1

Listing rule 3.1 requires an entity to give ASX immediately any information
concerning it that a reasonable person would expect to have a material effect
on the price or value of the entity's securities. The exceptions to this
requirement are set out in listing rule 3.1A.

In responding to this letter you should consult listing rule 3.1 and Guidance
Note 8 - Continuous Disclosure: listing rule 3.1.

If the information requested by this letter is information required to be given
to ASX under listing rule 3.1 your obligation is to disclose the information
immediately.

Your responsibility under listing rule 3.1 is not confined to, or necessarily
satisfied by, answering the questions set out in this letter.

Trading halt

If you are unable to respond by the time requested, or if the answer to
question 1 is yes and an announcement cannot be made immediately, you should
consider a request for a trading halt in the Company's securities. As set out
in listing rule 17.1 and Guidance Note 16 - Trading Halts we may grant a
trading halt at your request. We may require the request to be in writing. We
are not required to act on your request. You must tell us each of the
following.

* The reasons for the trading halt.

* How long you want the trading halt to last.

* The event you expect to happen that will end the trading halt.

* That you are not aware of any reason why the trading halt should not be
granted.

* Any other information necessary to inform the market about the trading
halt, or that we ask for.

The trading halt cannot extend past the commencement of normal trading on the
second day after the day on which it is granted. If a trading halt is requested
and granted and you are still unable to reply to this letter before the
commencement of trading, suspension from quotation would normally be imposed by
us from the commencement of trading if not previously requested by you. The
same applies if you have requested a trading halt because you are unable to
release information to the market, and are still unable to do so before the
commencement of trading.

If you have any queries regarding any of the above, please let me know.

Yours faithfully,

Julia Kagan

Adviser, Issuers (Melbourne)



Response:

22 August 2006


Ms Julia Kagan

Adviser, Issuer (Melbourne)

Australian Stock Exchange Limited

Level 3, Stock Exchange Centre

530 Collins Street

Melbourne Vic 3000


Dear Julia

Re: Phosphagenics Limited - Price Query

In response to your letter of 21 August the Company advises the following
responses:

1. No

2. Not applicable

3. As previously disclosed to ASX in the Company's 2005 Annual Report and
various announcements to ASX since that time, Phosphagenics has accelerated its
research programme, particularly its clinical (human) studies. In line with
this acceleration, Phosphagenics anticipates that the operating loss before
abnormal items and income tax for the half year ended 30 June 2006 will vary
materially (about $1.2 million greater) from the previous corresponding period.

4. No

5. Phosphagenics suggests that the following may provide some explanation for
the price changes and increase in volume in the securities of the Company:

A) Phosphagenics is aware that an offshore financial institution has acquired a
parcel of Phosphagenics' shares last week.

B) As previously reported to ASX on 24 July 2006 the Company commenced a
pivotal Phase I clinical trial its patented transdermal insulin delivery
platform. That announcement stated that the trial was expected to be completed
by the end of July with full analysis anticipated by September 2006. The
Company has no reason to expect that the receipt of the full analysis of the
trial and any consequence announcement to the ASX will not be within the
original time frame disclosed in the 24 July 2006 announcement. The Company is
also expecting a preliminary report from the principle investigator shortly and
will subsequently release details of this report.

6. We confirm the Company is in compliance with the Listing Rules, and in
particular Listing Rule 3.1.


Yours Faithfully

Phosphagenics Limited


Per Mourice Garbutt

Company Secretary

Getting better & better

stockdog, do you know anything about the following?

Phosphagenics is aware that an offshore financial institution has acquired a
parcel of Phosphagenics' shares last week.

I can't find it.

forest - no I don't , but isn't the ASX tedious - last year's accounts were barely readable for compliance guff and almost zilch info on the company. I always thought Ozzies were practical, easy-going folk, but ASX verges on the paranoid. Anything of real interest is ont he co's website, not in any formally required reporting.

I guess if the insti bought 3% or more PSG will have to announce this under AIM rules.

Think it more likely to be a strategic stake, rather than an opportunistic bete on soon to be released news, although no evidence to support this.

Another 3.5 years to run on my holding time frame, so plenty of time for one of thie products to really hit the market (apart from their vitE products already selling well).

sd

Thanks. Should get news soon on trials.